维罗纳制药 VRNA 深 沪
已收盘 10-07 16:00:00 美东时间
106.91
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 106.91
- 总市值 91.93亿
- 52周最高 106.93
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 31.60
- 委 比 0.00%
- 总股本 8599.13万
- 历史最高 106.93
- 量 比 0
- 振 幅 0.00%
- 历史最低 2.01
- 每 手 1
- 风险率 19.18%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多UPDATE 2-Merck's 2026 outlook clouds upbeat fourth-quarter results
UPDATE 2-Merck's 2026 outlook clouds upbeat fourth-quarter results Co expects 2026 sales of $65.5 bln-$67 bln vs analysts' estimate $67.6 bln Reports Q4 sales of $16.4 bln, with Keytruda contributing $8.37 bln CEO Davis says still on the lookout for deals Adds analyst comments in paragraphs 5 and 10
02-03 19:40
UPDATE 1-Merck forecasts 2026 sales below estimates on patent losses
UPDATE 1-Merck forecasts 2026 sales below estimates on patent losses Expects 2026 sales $65.5 bln-$67 bln; analysts estimating $67.6 bln Q4 sales were $16.4 bln, with Keytruda contributing $8.37 bln CEO Davis says still on the lookout for deals Adds shares in paragraph 3 By Michael Erman Feb 3 (Reut
02-03 19:40
Merck & Co. meldet für das vierte Quartal 2025 ein den Aktionären zurechenbares Nettoergebnis von 2.963 Mio. USD, ein Rückgang um 21 Prozent
Merck & Co. meldet für das vierte Quartal 2025 ein den Aktionären zurechenbares Nettoergebnis von 2.963 Mio. USD, ein Rückgang um 21 Prozent Merck & Co. Inc. hat die Finanzergebnisse für das vierte Quartal sowie das Gesamtjahr 2025 veröffentlicht. Das den Aktionären zurechenbare Nettoergebnis belief
02-03 19:31
Merck posts Q4 diluted EPS of USD 1.19, down 20%
Merck posts Q4 diluted EPS of USD 1.19, down 20% Merck & Co. Inc. reported its financial results for the fourth quarter (Q4) and full year (FY) 2025. For Q4 2025, net income attributable to shareholders was USD 2.96 billion, with diluted earnings per share (EPS) of USD 1.19. For the full year 2025,
02-03 19:31
Merck forecasts 2026 sales below estimates on patent losses
Merck forecasts 2026 sales below estimates on patent losses Expects 2026 sales $65.5 bln-$67 bln; analysts estimating $67.6 bln Q4 sales were $16.4 bln, with Keytruda contributing $8.37 bln CEO Davis says still on the lookout for deals By Michael Erman Feb 3 (Reuters) - Merck & Co MRK.N on Tuesday f
02-03 19:30
The Year-End 2025 Biotech Rally And What It Means For 2026
Biotechnology stocks are wrapping up 2025 on a high note, bouncing back from a ...
2025-12-31 23:54
Merck acquisition of Verona Pharma approved by court
Merck's (NYSE:MRK) ~$10B acquisition of Verona Pharma (NASDAQ:VRNA) has been granted approval by the High Court of Justice of England and Wales. Under terms, MSD, the trade name of Merck outside the U...
2025-10-07 04:46
Verona Pharma Announces That High Court Of Justice Of England And Wales Has Approved Its Acquisition By MSD For $107 Per American Depository Share, Totaling ~$10B
Verona Pharma plc (NASDAQ:VRNA) ("Verona Pharma"), a biopharmaceutical company focused on respiratory diseases, which entered into a definitive agreement on July 8, 2025 relating to its proposed acquisition by MSD
2025-10-07 04:07
